Chris Irons: Something Will Break, Sharp Deleveraging, The Fed Folds, & Gold Could Hit $7,500
Speakers
Chris Irons
— Financial Commentator and Author, QTR's Fringe Finance
Summary
Chris Irons assesses markets as historically overvalued and propped up by passive flows, warns a sharp deleveraging is coming, and argues the Fed will fold quickly. He outlines several investable ideas including equal-weight S&P, gold, gold miners, psychedelics, and emerging markets, while urging avoidance of regional banks.
- Markets are at or above the highest valuations in history, driven by passive bids and options flows rather than fundamentals.
- Irons believes the Fed is trapped and will not tolerate equity market pain; any 10-20% drop will force them to ease aggressively.
- Gold and gold miners (GDX, SIL) are favorite buys for a post-crisis rally; gold could reach $7,500 after the next round of money printing.
- Psychedelics (CMPS, MNMD, PSI ETF) are his top sector idea for 2025, citing regulatory tailwinds and big pharma validation.
- He recommends an equal-weighted S&P 500 ETF (RSP) to reduce concentration risk from the top 10 mega-cap names.
- Emerging markets (EEM) are expected to outperform US equities as the extreme valuation gap eventually closes.
- Regional banks (KRE) should be avoided due to heavy commercial real estate exposure and unmarked books.
- Underappreciated risks include crypto leverage, unaudited stablecoins, private credit, and off-balance-sheet corporate shenanigans.
Ideas
Equal-weight S&P will outperform cap-weighted.
The market-cap-weighted S&P 500 is dangerously concentrated in overvalued mega-cap names. An equal-weighted S&P 500 ETF (RSP) reduces that concentration risk and should outperform as market breadth improves or when the market corrects.
Psychedelic stocks poised for asymmetric gains.
The psychedelic drug sector is an asymmetric upside opportunity. It is underfollowed, clinical trial data is positive, regulatory tailwinds are emerging (RFK Jr., FDA fast-tracking), and big pharma validation arrived with Eli Lilly's acquisition of Atai. Stocks like Compass Pathways, Definium/MindMed, and the PSI ETF stand to benefit significantly.
Emerging markets will outperform US stocks.
The valuation gap between the US market and the rest of the world is extreme. The US P/E multiple must contract while the rest-of-world multiple expands, driving outperformance of emerging markets (EEM) over US equities.
Gold miners undervalued, ready to surge.
Gold miners have pulled back sharply while gold remains elevated. The GDX has fallen from ~120 to ~75, P/E multiples contracted significantly, and miners still extract gold at low cost. This divergence creates an attractive entry for a sector that will surge when gold rallies again.
Gold to $7,500 after Fed prints.
Gold is a long-term bull due to monetary debasement, relentless Fed printing, and a weakening dollar. After a sharp deleveraging event that initially sells off gold, the Fed will intervene with massive stimulus, sending gold to $7,500 or higher within 12-18 months.
Avoid regional banks, CRE exposure risk.
Regional banks are heavily exposed to commercial real estate bubbles, unmarked books, subprime auto, and a struggling consumer. These risks make the sector fragile and unattractive as rates stay elevated.
